Clinical Trials · NCT01619345
Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 27
- Start date
- Jun 2012
- Locations
- 1 site, United Kingdom
- Primary endpoint
- Anatomical location (stomach or proximal small bowel) of tablet at complete tablet erosion (CTE)